Gsa Capital Partners LLP Cti Biopharma Corp Transaction History

Gsa Capital Partners LLP

  • $1.32 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023
SELL
$4.45 - $6.17 $247,531 - $343,206
-55,625 Reduced 41.4%
78,729 $473,000
Q3 2022

Nov 14, 2022
BUY
$5.36 - $7.43 $720,137 - $998,250
134,354 New
134,354 $782,000

About CTI BIOPHARMA CORP

CTIC Quotes by TradingView
  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email